Search results for "Lipid disorders"

showing 3 items of 3 documents

Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey

2009

Background: Fabry disease is a rare X-linked lysosomal storage disorder characterised by severe multisystemic involvement that leads to major organ failure and premature death in affected men and women. Over the past 7 years, the Fabry Outcome Survey (FOS) has collected data on the natural history of Fabry disease, and the long-term efficacy and safety of enzyme-replacement therapy. This paper provides an update on the first analysis of FOS data. Design: Baseline data on clinical manifestations and causes of death in a cohort of 1453 patients (699 male, 754 female) from 19 countries worldwide were analysed. Causes of death of affected relatives were analysed separately. Results: The most fr…

AdultMalemedicine.medical_specialtyMetabolic disordersCardiomyopathyDisease030204 cardiovascular system & hematologyCohort Studies03 medical and health sciencesSex Factors0302 clinical medicineCause of DeathInternal medicineGeneticsmedicineHumansLipid disordersGenetic epidemiologyChildGenetics (clinical)Cause of deathChi-Square DistributionVascular diseasebusiness.industryData CollectionEnzyme replacement therapymedicine.diseaseFabry disease3. Good healthCohortFabry DiseaseFemaleKidney Diseasesbusiness030217 neurology & neurosurgeryCohort studyJournal of Medical Genetics
researchProduct

Management of homozygous familial hypercholesterolaemia in two brothers

2018

Homozygous familial hypercholesterolaemia (HoFH) is a rare, genetic disorder of abnormally high levels of low-density lipoprotein cholesterol (LDL-C) requiring aggressive interventions to retard the evolution of atherosclerotic cardiovascular disease. We treated two brothers (ages 46 years and 47 years) with HoFH with statins, lipoproteinapheresis (LA) and the microsomal triglyceride transfer protein inhibitor lomitapide. Both brothers carried the p.Thr434Arg homozygous LDLR mutation and had childhood total cholesterol levels >700 mg/dL. Inter-LA LDL-C levels remained high; therefore, they were given escalating doses of oral lomitapide (5–10 mg/day). One brother was able to maintain LDL-C l…

Malemedicine.medical_specialty1523030204 cardiovascular system & hematologyMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRare DiseaseTotal cholesterolInternal medicinelipid disordersmedicineHumans1506030212 general & internal medicineLipoprotein cholesterolcongenital disordersbiologyAtherosclerotic cardiovascular diseasebusiness.industryAnticholesteremic AgentsSiblingsHomozygoteGenetic disorderGeneral MedicineMiddle Agedmedicine.diseaseLomitapideendocrine systemEndocrinologyReceptors LDLchemistryMutationLDL receptorbiology.proteinBenzimidazoleslipids (amino acids peptides and proteins)businessRare diseaseBMJ Case Reports
researchProduct

Wytyczne PTL/KLRWP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce 2021

2021

therapyleczeniehypercholesterolemiaczynniki ryzykamiażdżycowa choroba sercowo-naczyniowazaburzenia lipidowediagnostykaprofilaktykapreventionaherosclerotic cardiovascular diseasediagnosticslipid disordersrisk factorshipercholesterolemiaDiagnostyka Laboratoryjna
researchProduct